TC BioPharm (TCBP) has signed a non-binding letter of intent (LoI) to acquire an ophthalmic pharmaceutical company focused on commercialising intraocular pressure-minimising therapies for individuals ...

Shares of clinical-stage biopharmaceutical company TC BioPharm Plc TCBP are continuing to trade higher Wednesday after the company on Tuesday announced a strategic collaboration to advance gamma-delta ...

Shenzhen, China--(Newsfile Corp. - May 9, 2024) - Kexing Biopharm recently took an important step forward in cancer therapy. Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a ...

(RTTNews) - TC BioPharm (TCBP), a clinical-stage biotechnology company, on Thursday announced the successful completion of dosing for Cohort A in the ACHIEVE Phase 2B UK clinical trial. The trial ...

Samyang Biopharm, a medical devices and biopharmaceutical affiliate of Samyang Group, soared on the Kospi on Monday as it made its debut on Korea’s main bourse after a spin-off from Samyang Holdings.

BOSTON--(BUSINESS WIRE)--Infinata today announced the latest release of BioPharm Clinical, the leading tool to expedite study feasibility and clinical operations. This release features a completely ...

XuanZhu BioPharm and Chemical.AI announce collaboration focusing on cancer, metabolism, digestion and other fields, jointly to develop new drugs with proprietary intellectual property rights. Back in ...

MIAMI--(BUSINESS WIRE)--Increased scrutiny and regulation in the nutraceutical and supplement market should be welcomed according to BioPharm CEO, Rafael Olartecoechea, producer of Vimulti® ...

TC BioPharm shares are trading lower by 44% Wednesday morning. The company announced the pricing of an offering of 2 million units at $1 per unit. Get Discounted Real-Time Trade Alerts For a Volatile ...